A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Aug 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 17 Aug 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.